| abstract |
The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 3.5 and 4.4, comprising at least human insulin A21G and at least one prandial glucagon suppressor. In one embodiment, the prandial glucagon suppressor is selected from the group consisting of an amylin analog or an amylin receptor agonist or a GLP-1 analog or a GLP receptor agonist. -1 (GLP-1 RA). In one embodiment, the prandial glucagon suppressor is an amylin analogue or an amylin receptor agonist. In one embodiment, the prandlease glucagon suppressor peptide is pramlintide. It also relates to a method for obtaining the human insulin A21G comprising at least one step of reacting the human insulin A21G, B31R, B32R (insulin glargine) with the rat carboxypeptidase B at an insulin / carboxypeptidase ratio between 500 and 2000, at a pH of 7.5 to 8.5 and at a temperature of 20 to 30 ° C for 10 to 20 hours. |